Sprycel

Leukemia, Myeloid, Accelerated Phase, Acute Lymphoblastic Leukemia, Chemotherapy + 4 more
Treatment
12 FDA approvals
20 Active Studies for Sprycel

What is Sprycel

DasatinibThe Generic name of this drug
Treatment SummaryDasatinib is a drug used to treat chronic myelogenous leukemia (CML). It works by inhibiting four different types of enzymes: BCRABL, SRC, Ephrins, and GFR. It is taken orally and is approved for use in patients with CML.
Sprycelis the brand name
image of different drug pills on a surface
Sprycel Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sprycel
Dasatinib
2006
7

Approved as Treatment by the FDA

Dasatinib, also called Sprycel, is approved by the FDA for 12 uses like Myeloid Leukemia, Chronic, Chronic Phase and blast phase Chronic myelocytic leukemia .
Myeloid Leukemia, Chronic, Chronic Phase
blast phase Chronic myelocytic leukemia
Chronic Myeloid Leukemia (CML)
Acute Lymphoblastic Leukemia (ALL)
Accelerated phase chronic myologenic leukemia
Newly Diagnosed
Leukemia, Myeloid, Chronic-Phase
Therapeutic procedure
Leukemia, Myeloid, Accelerated Phase
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemotherapy
Acute Lymphoblastic Leukemia

Effectiveness

How Sprycel Affects PatientsDasatinib is an oral medication that helps to stop two types of proteins (BCR/ABL and Src family tyrosine kinase) from growing in the body.
How Sprycel works in the bodyDasatinib is a drug that works by stopping certain proteins from functioning. It specifically targets the proteins in the BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ groups. Studies have shown that dasatinib can stop the growth of leukemia cells that overexpress BCR-ABL, and can also overcome resistance caused by mutations and other drug resistance genes.

When to interrupt dosage

The suggested dosage of Sprycel is reliant upon the diagnosed condition. The amount of dosage is contingent upon the method of delivery (e.g. Powder, for suspension or Oral) as described in the table beneath.
Condition
Dosage
Administration
Leukemia, Myeloid, Accelerated Phase
70.0 mg, , 20.0 mg, 50.0 mg, 100.0 mg, 80.0 mg, 140.0 mg, 10.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Acute Lymphoblastic Leukemia
70.0 mg, , 20.0 mg, 50.0 mg, 100.0 mg, 80.0 mg, 140.0 mg, 10.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Chemotherapy
70.0 mg, , 20.0 mg, 50.0 mg, 100.0 mg, 80.0 mg, 140.0 mg, 10.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
70.0 mg, , 20.0 mg, 50.0 mg, 100.0 mg, 80.0 mg, 140.0 mg, 10.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Newly Diagnosed
70.0 mg, , 20.0 mg, 50.0 mg, 100.0 mg, 80.0 mg, 140.0 mg, 10.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Leukemia, Myeloid, Chronic-Phase
70.0 mg, , 20.0 mg, 50.0 mg, 100.0 mg, 80.0 mg, 140.0 mg, 10.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Therapeutic procedure
70.0 mg, , 20.0 mg, 50.0 mg, 100.0 mg, 80.0 mg, 140.0 mg, 10.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral

Warnings

There are 20 known major drug interactions with Sprycel.
Common Sprycel Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Dasatinib is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Dasatinib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Dasatinib.
Abetimus
Major
The risk or severity of adverse effects can be increased when Dasatinib is combined with Abetimus.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Dasatinib.
Sprycel Toxicity & Overdose RiskAnimals who take too much of this drug at once may experience heart damage.
image of a doctor in a lab doing drug, clinical research

Sprycel Novel Uses: Which Conditions Have a Clinical Trial Featuring Sprycel?

177 active clinical trials are investigating the potential of Sprycel as a novel therapeutic strategy for Acute Lymphoblastic Leukemia treatment.
Condition
Clinical Trials
Trial Phases
Acute Lymphoblastic Leukemia
118 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Chemotherapy
4 Actively Recruiting
Phase 1, Phase 3, Not Applicable
Leukemia, Myeloid, Chronic-Phase
3 Actively Recruiting
Phase 2, Phase 1
Newly Diagnosed
3 Actively Recruiting
Phase 3, Phase 1
Leukemia, Myeloid, Accelerated Phase
0 Actively Recruiting
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting

Sprycel Reviews: What are patients saying about Sprycel?

5Patient Review
2/15/2014
Sprycel for Type of Leukemia - Chronic Myelogenous Leukemia
I'm in remission and this drug definitely played a role in that. Sure, there are some not-so-great side effects like diarrhea and bone pain, but it's worth it to me. I'll have to take this medication for the rest of my life, but that's a small price to pay.
5Patient Review
7/4/2016
Sprycel for Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
I had a pounding headache and pain in my ear that felt like worms boring into it.
5Patient Review
6/2/2013
Sprycel for Chronic Phase Chronic Myeloid Leukemia
I've been on Sprycel for a little over a year now and I'm feeling pretty good. My blast cell count has decreased significantly, which is great news. The only downside is that I sometimes get tired and my arms will ache if I carry anything heavy.
4.7Patient Review
10/21/2015
Sprycel for Chronic Phase Chronic Myeloid Leukemia
I've been on the medication for about 2 months and have had chronic gastrointestinal issues since then. Dairy products make it worse, has anyone else experienced this?
4.7Patient Review
1/2/2018
Sprycel for Chronic Phase Chronic Myeloid Leukemia
After six weeks, I had a bad reaction in the form of itchy red welts on my arms and legs.
4.7Patient Review
8/6/2014
Sprycel for Chronic Phase Chronic Myeloid Leukemia
The worst side effect I experienced was mouth sores, but I also had headaches and joint pain at first. However, they both went away after a month or so. I stopped responding to the treatment after 10 months.
4.7Patient Review
4/27/2013
Sprycel for Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
Great results, but unfortunately I experienced some fatigue, confusion, and depression.
4.3Patient Review
2/2/2013
Sprycel for Chronic Phase Chronic Myeloid Leukemia
I began treatment with Gleevec, but unfortunately it only caused me more pain. I was eventually switched to Sprycel, which has helped me enter remission; however, the 50mg dose causes a lot of other issues like fatigue and bone pain.
4.3Patient Review
7/21/2015
Sprycel for Chronic Phase Chronic Myeloid Leukemia
Sprycel was effective for me in remissioning my CML within about a year of starting treatment. I had some moderate side effects at first including skin rashes, adult acne, nausea, muscle aches and extreme fatigue; however, these lessened as my dosage was reduced by my doctor. The only issue I'm having now is with blood pressure.
4.3Patient Review
4/18/2019
Sprycel for Chronic Phase Chronic Myeloid Leukemia
I was diagnosed with CML 2.5 years ago and have experienced nearly every side effect imaginable: joint pain, nausea, serious fatigue, very high blood pressure, painful acne, constipation. If there's a side effect out there, I've probably had it. I wish I could take a break from the medication but my doctor won't allow it. I've been in remission for almost a year now and am grateful that the treatment has been successful. But at the end of the day, cancer sucks!
4.3Patient Review
1/8/2016
Sprycel for Chronic Myelocytic Leukemia in the Accelerated Phase
I've encountered some chronic fatigue while using sprycel, which has made it tough to get my insurance company to foot the bill. I'm curious how others have fared in this department.
4Patient Review
2/2/2013
Sprycel for Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
I've experienced some pretty intense bone pain as a result of both the Gleevec and Sprycel treatments. Unfortunately, Gleevec stopped working for me and Sprycel has caused a number of other problems in addition to the bone pain. I'm now disabled because of the side effects from both the disease and the medication
4Patient Review
5/25/2021
Sprycel for Chronic Phase Chronic Myeloid Leukemia
I was diagnosed in 2004 at age 46. I started on Gleevic 400 mg and saw great results with only minor side effects. However, after eight years it stopped being effective. So, then I switched to Sprycel 100 mg but experienced terrible fever and acne breakouts as a result. My doctor didn't want to reduce the dosage, but I eventually convinced him/her too lower it to 50 mg. It's still working now, 17 years later; however, I have developed shortness of breath from the Sprycel which is concerning.
3.7Patient Review
10/8/2014
Sprycel for Chronic Phase Chronic Myeloid Leukemia
Sprycel has been helping me since 2010, though it comes with some nasty side effects like nausea and vomiting. My heart rate increased and I had to start taking blood pressure medication. In 2014, I started experiencing severe joint and back pain. Thankfully, we have these pills to help us out, even if they come with a price.
2.7Patient Review
3/25/2014
Sprycel for Chronic Phase Chronic Myeloid Leukemia
I started taking the medication in January 2014 and experienced a drastic reduction in platelet count. I then stopped taking the medication for over one month, but when I began again, the side effects were worse. I experienced reductions in RBC count and platelet count, weight gain, headaches, tiredness, depression, and chest pain.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sprycel

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is sprycel a chemotherapy?

"Sprycel is not a chemotherapy drug, but is used to treat certain types of leukemia. Chemotherapy drugs work by killing cells that grow and multiply rapidly, including cancer cells."

Answered by AI

How long do you take Sprycel for CML?

"Typically, Sprycel is taken long-term, as clinical trials have proven its efficacy for up to five years. You and your doctor will decide how long to continue treatment based on how well your tests show the drug is working."

Answered by AI

What are the side effects of the drug Sprycel?

"Although not everyone experiences them, the following side effects are considered the most common in people taking SPRYCEL: diarrhea, headache, skin rash, shortness of breath, fatigue, nausea, and muscle pain."

Answered by AI

What is the drug Sprycel used for?

"SPRYCEL® is a prescription medicine used to treat: Adults with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) Adults with Ph+ CML who no longer benefit from, or did not tolerate, other treatment, including imatinib."

Answered by AI

Clinical Trials for Sprycel

Image of St. Jude Children's Research Hospital in Memphis, United States.

Tirzepatide + Resistance Exercise for Obesity in ALL Survivors

18+
All Sexes
Memphis, TN
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \<5% unacceptable.
Phase 2
Waitlist Available
St. Jude Children's Research HospitalStephanie B Dixon, MD, MPH
Image of UPMC Hillman Cancer Center in Pittsburgh, United States.

Mobile App for Cancer

18+
All Sexes
Pittsburgh, PA
The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving chemotherapy. The main questions it aims to answer are: * Is the mobile application feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment? Participants will: * Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * Complete daily symptom ratings via study application. * Wear a Fitbit activity tracker for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study. * Optional: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).
Waitlist Available
Has No Placebo
UPMC Hillman Cancer CenterCarissa A Low
Have you considered Sprycel clinical trials? We made a collection of clinical trials featuring Sprycel, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

CMV-MVA Triplex Vaccine for Cancer

18 - 75
All Sexes
Duarte, CA
This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and/or effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.
Phase 1
Waitlist Available
City of Hope Medical Center (+2 Sites)Ryotaro Nakamura
Image of Juravinski Hospital in Hamilton, Canada.

RBC Transfusion Strategy for Leukemia

18+
All Sexes
Hamilton, Canada
This pilot study aims to gather preliminary evidence on how different hemoglobin levels impact blood biomarkers related to bleeding. The feasibility of conducting a future larger clinical trial will also be assessed. Red blood cell transfusions are part of the standard of care for patients with leukemia. This study evaluates two transfusion strategies: one that maintains hemoglobin levels above the standard-of-care threshold, reflecting current routine practice; and another that maintains hemoglobin levels above 110 g/L, which is closer to the normal hemoglobin range. The normal hemoglobin range is 120-160 g/L for females and 140-180 g/L for males. Raising hemoglobin levels closer to normal values may reduce bleeding risk.
Recruiting
Has No Placebo
Juravinski Hospital
Have you considered Sprycel clinical trials? We made a collection of clinical trials featuring Sprycel, we think they might fit your search criteria.Go to Trials
Image of MD Anderson in Houston, United States.

Cyclophosphamide-Based Prophylaxis for Leukemia

18 - 66
All Sexes
Houston, TX
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination. Participants will: * Receive the standard or new drug combination after transplant * Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients * Take surveys about physical and emotional well-being * Give blood and stool samples.
Phase 2
Recruiting
MD Anderson (+2 Sites)Incyte Corporation
Image of St. Jude Children's Research Hospital in Memphis, United States.

CAR T Cell Therapy for Acute Lymphoblastic Leukemia

< 65
All Sexes
Memphis, TN
CAR19PK is a research study evaluating the use of lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of refractory and/or relapsed leukemia. For this type of therapy, peripheral (circulating) immune cells are collected and then modified so that they can recognize an antigen, which is a particle present on the surface of a cancer cell. The CD19-CAR T cell product will be manufactured at the St. Jude Children's Research Hospital's Good Manufacturing Practice (GMP) facility. The main purpose of this study is to determine: * Evaluate different doses of fludarabine prior CAR T cell infusion * How your body processes fludarabine and cyclophosphamide, * How long the CAR T cells last in the body, * Whether or not treatment with this therapy is effective in treating people with refractory or relapsed leukemia, and * The side effects of this therapy.
Phase 2
Recruiting
St. Jude Children's Research HospitalAimee Talleur, MD
Image of City of Hope Medical Center in Duarte, United States.

Vedolizumab + Cyclophosphamide + Tacrolimus for Graft-versus-Host Disease

18 - 80
All Sexes
Duarte, CA
This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced intensity conditioning. Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a donor. Giving reduced conditioning chemotherapy before an allogeneic HCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new stem cells to grow using less than standard doses of chemotherapy. Sometimes, the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Vedolizumab is a monoclonal antibody, which is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). It may reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus suppresses the immune system by preventing the activation of certain types of immune cells. Giving vedolizumab plus PTCy and short course tacrolimus may be effective at preventing GVHD after allogeneic HCT.
Phase 2
Recruiting
City of Hope Medical CenterMonzr M. Al Malki
Have you considered Sprycel clinical trials? We made a collection of clinical trials featuring Sprycel, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security